Cytoflavin (Inosine/nicotinamide/riboflavin/succinic acid) / POLYSAN - LARVOL DELTA

Results of the observational program CITOTREK (use of the drug CITOflavin in Tablets) in patients with tension headaches against the backgRound of asthenic syndromE taKing into account comorbidity (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The results of the study allow us to consider the drug Cytoflavin in the treatment regimens for comorbid patients with TTH in asthenic disorders."

Clinical • Journal • Cardiovascular • CNS Disorders • Depression • Hypertension • Mood Disorders • Pain • Psychiatry • Pulmonary Arterial Hypertension • Sleep Disorder

Oxidative stress and depression in Parkinson's disease (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The results of a comparative analysis of the effectiveness of treatment of depression in patients with Parkinson's disease showed that the use of a combination of Fluvoxamine and Cytoflavin provides a more pronounced therapeutic effect compared with Fluvoxamine monotherapy. These findings emphasize the need to integrate combined approaches into the development of new treatment strategies for depressive states based on a personalized assessment of the clinical picture of depressive disorder and biomarkers of oxidative stress."

Journal • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Comparative study of the neuroprotective effects of the drug Cytoflavin and citicoline in a rats model of hemorrhagic stroke (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The comparative study of the neuroprotective effects of CF and CC in a rat model of HS revealed that both drugs significantly reduced brain edema and neurological deficits related to sensorimotor and cognitive impairments. CC showed a slight psychostimulatory effect and a shorter duration of action after treatment cessation, while CF exhibited a longer-lasting effect on brain tissue edema, cognitive, and sensorimotor functions after discontinuation. The separate series with only 10-day intravenous CF administration was insufficient to achieve a stable therapeutic effect, suggesting that the continuation of CF treatment with oral forms is required to maintain long-term benefits in the context of experimental HS in rats."

Clinical • Journal • Preclinical • Alzheimer's Disease • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Cognitive Disorders • Hematological Disorders

Cytoflavin in the Complex Rehabilitation of Stroke Patients (clinicaltrials.gov) - P3 | N=240 | Completed | Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Recruiting ➔ Completed

Trial completion • Cardiovascular

Clinical and instrumental diagnostics of facial neuropathy in children (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "A review of the literature and the authors' own long-term experience of developing and implementing into practice an algorithm for clinical and instrumental diagnostics of facial nerve neuropathy in children are presented, allowing, in the early stages of the disease, taking into account the identified values of prognostically significant indicators, to predict the outcome of the disease and develop an individual medical rehabilitation program to achieve maximum restoration of nerve function. The expediency of using Cytoflavin (Inosine+Nicotinamide+Riboflavin+Succinic acid) as a drug with complex action in the treatment of severe neuropathies of the facial nerve is reflected."

Journal • Review • Pain

THE COMBINATION OF INOSINE, NICOTINAMIDE, RIBOFLAVIN AND SUCCINIC ACID IN THE COMPLEX REHABILITATION OF STROKE SURVIVORS: A MULTICENTER DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMIZED STUDY (ESOC 2025) - P3 | "We enrolled 240 subjects (March 2023 - June 2024), 221 (93%) had ischemic stroke, 176 (74%) were 14-45 days post stroke, median age 66 (IQR 54-78), males 129 (54%). In the experimental group (n=121), the average change of COPM performance score was 3.41 vs. 2.55 in the placebo group (n=117) (p<0.001; 96% CI for the difference exceeded the prespecified superiority margin)."

Clinical • Late-breaking abstract • Cardiovascular • Ischemic stroke

Cognitive impairment after major surgical operations (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Most of the risk factors for deferred cognitive impairment are preoperative, which allows ahead additional assessment of the possibility of modifying the surgical technique and accompanying therapy, as well as designing of personalized tactics of cerebroprotection and prevention of cognitive impairment."

Journal • Alzheimer's Disease • Atherosclerosis • Cardiovascular • CNS Disorders • Cognitive Disorders • Dyslipidemia • Oncology

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy (clinicaltrials.gov) - P=N/A | N=562 | Recruiting | Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Trial completion date: Mar 2025 ➔ Nov 2025 | Trial primary completion date: Dec 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke

Adjuvant pharmacological modulation with Cytoflavin in rehabilitation at stages 2-3 in patients with acute cerebral insufficiency and post-intensive care syndrome (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "To further evaluate the efficacy of Cytoflavin (Inosine+Nicotinamide+Riboflavin+Succinic Acid) in post-intensive care syndrome (PICS) in patients who have suffered ischemic stroke and to present the design of a new prospective study on the rehabilitation of PIC syndrome in patients with acute cerebral insufficiency (ACI). The study is scheduled to be conducted from May 2024 to October 2025. The results of the planned prospective study will clarify the feasibility of including Cytoflavin in clinical recommendations for the treatment of PICS at the stages of rehabilitation treatment."

Journal • Cardiovascular • Critical care • Ischemic stroke

Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages of Rehabilitation of Patients With Post Intensive Care Syndrome (clinicaltrials.gov) - P=N/A | N=90 | Recruiting | Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Trial completion date: Sep 2025 ➔ May 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Critical care • Ischemic stroke

Autoimmune diseases of central nervous system and respiratory viral infections in children (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The authors give characteristics of influenza virus, measles and SARS-CoV-2 virus as infectious agents- triggers of autoimmune central nervous system diseases. Modern possibilities to strenghen a patogenic therapy by Cytoflavin, which has a complex effect aimed at improving metabolic processes in the brain, are presented."

Journal • Review • CNS Disorders • Immunology • Infectious Disease • Influenza • Measles • Novel Coronavirus Disease • Respiratory Diseases

The effectiveness of Cytoflavin in the medical rehabilitation of elderly and senile patients (PubMed, Ter Arkh) - "The standard course of Cytoflavin therapy in the medical rehabilitation of elderly and senile patients after pneumonia associated with COVID-19 significantly reduces the severity of cognitive impairment, fatigue and depressive disorders, improves indicators of the emotional and volitional sphere, increases exercise tolerance."

Clinical • Journal • Observational data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Fatigue • Infectious Disease • Mood Disorders • Novel Coronavirus Disease • Pneumonia • Psychiatry • Respiratory Diseases

Comprehensive rehabilitation of spinal trauma patients with extended involvement of nursing staff and neurometabolic therapy (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "The use of the drug Cytoflavin and classes using the Bobata method with the participation of a nurse of the department significantly increases the effectiveness of therapeutic measures in patients with PSMT."

Journal • CNS Disorders • Orthopedics

Evaluation of the Efficacy of Permanent Course Combined Therapy with CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, At 2-3 Stages of Rehabilitation of Patients with Post Intensive Care Syndrome (clinicaltrials.gov) - P=N/A | N=90 | Recruiting | Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company

New trial • Cardiovascular • Critical care • Ischemic stroke

Cytoflavin in the Complex Rehabilitation of Stroke Patients (clinicaltrials.gov) - P3 | N=196 | Recruiting | Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Trial primary completion date: Sep 2024 ➔ Dec 2024

Trial primary completion date • Cardiovascular